T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AAN.A
476
DELISTED
The Aaron's Company Inc Class A
AAN.A
| $165M | 0.03% |
5,839,744
-513,730
| -8% | -$14.5M |
|
477
Belden
BDC
$5.39B
| $165M | 0.03% |
1,760,483
-145,980
| -8% | -$12.6M |
|
|
DTV
478
DELISTED
DIRECTV COM STK (DE)
DTV
| $164M | 0.03% |
1,932,830
-658,082
| -25% | -$56.8M |
|
479
Novavax
NVAX
$1.31B
| $164M | 0.03% |
993,377
+374,522
| +61% | +$60.8M |
|
|
AVNS
480
DELISTED
Avanos Medical
AVNS
| $164M | 0.03% |
3,338,970
+149,035
| +5% | +$6.9M |
|
|
ARUN
481
DELISTED
ARUBA NETWORKS, INC.
ARUN
| $164M | 0.03% |
6,701,149
-397,932
| -6% | -$8.01M |
|
482
Armstrong World Industries
AWI
$7.75B
| $164M | 0.03% |
2,852,020
-4,010
| -0.1% | -$215K |
|
|
DPLO
483
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $163M | 0.03% |
4,861,808
-93,870
| -2% | -$2.55M |
|
|
GRFS
484
Grifois
GRFS
$5.4B
| $163M | 0.03% |
+9,924,360
| New | +$166M |
|
485
WEX
WEX
$6.48B
| $163M | 0.03% |
1,515,149
+420,470
| +38% | +$42.4M |
|
|
USG
486
DELISTED
Usg
USG
| $162M | 0.03% |
6,065,850
+7,700
| +0.1% | +$218K |
|
487
United Therapeutics
UTHR
$21.9B
| $161M | 0.03% |
934,266
-22,629
| -2% | -$3.45M |
|
|
KRFT
488
DELISTED
KRAFT FOODS GROUP INC COM STK (VA)
KRFT
| $160M | 0.03% |
1,841,851
+462,606
| +34% | +$30.5M |
|
489
Kemper
KMPR
$1.56B
| $160M | 0.03% |
4,094,664
-189,060
| -4% | -$6.98M |
|
490
Five Below
FIVE
$13.2B
| $159M | 0.03% |
4,478,030
-3,338,980
| -43% | -$112M |
|
491
Southwest Gas
SWX
$6.68B
| $159M | 0.03% |
2,732,710
-311,390
| -10% | -$18.4M |
|
492
Glacier Bancorp
GBCI
$6.4B
| $159M | 0.03% |
6,309,396
-123,630
| -2% | -$3.06M |
|
493
Aon
AON
$74.7B
| $158M | 0.03% |
1,647,289
+54,427
| +3% | +$5.27M |
|
|
FNGN
494
DELISTED
Financial Engines, Inc.
FNGN
| $158M | 0.03% |
3,784,289
+16,800
| +0.4% | +$662K |
|
|
DO
495
DELISTED
Diamond Offshore Drilling
DO
| $158M | 0.03% |
5,896,932
+41,080
| +0.7% | +$1.28M |
|
496
ScottsMiracle-Gro
SMG
$3.62B
| $157M | 0.03% |
2,337,429
-17,993
| -0.8% | -$1.17M |
|
|
CKH
497
DELISTED
Seacor Holdings Inc.
CKH
| $156M | 0.03% |
2,318,191
+17,699
| +0.8% | +$1.22M |
|
498
TriNet
TNET
$3.07B
| $156M | 0.03% |
4,429,242
+501,724
| +13% | +$17.3M |
|
499
Pebblebrook Hotel Trust
PEB
$2.04B
| $155M | 0.03% |
3,332,346
-81,210
| -2% | -$3.87M |
|
500
Adtran
ADTN
$665M
| $155M | 0.03% |
8,304,198
+34,615
| +0.4% | +$736K |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.